API | cinoxacin

cinoxacin (cinobac) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Cinoxacin is a synthetic antibacterial agent for oral administration. Cinoxacin mode of action involves the inhibiting of DNA gyrase, a type II topoisomerase, and topoisomerase IV. Adverse effects are nausea, anorexia, vomiting, abdominal cramps/pain, perverse taste, diarrhea, headache, dizziness, rash, urticaria, pruritus, edema and other. ^NCATS

Chemistry

SMILES: CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2
InChIKey: VDUWPHTZYNWKRN-UHFFFAOYSA-N
Mol. Mass: 262.2182
ALogP: 2.65 Partition coefficient
ChEMBL Molecules:

tripelennamine hydrochloride

tripelennamine citrate

cinoxacin

tripelennamine

pyribenzamine

More Chemistry

Pharmacology

Mechanism of Action:
- DNA gyrase subunit A (Escherichia coli K-12) ^UniProt
- DNA gyrase subunit B (Escherichia coli K-12) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Oral
Pro Drug: No

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Urinary Tract Infections (approved 1980)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Urinary Tract Infections ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue